We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





New Test to Detect T-Cell Immune Response to SARS-CoV-2 Using AI-Powered Platform Delivers Results in Real-Time

By LabMedica International staff writers
Posted on 27 Oct 2021
Print article
Image: Hyris Test quickly detects T-Cell response to SARS-CoV-2 (Photo courtesy of Hyris Ltd.)
Image: Hyris Test quickly detects T-Cell response to SARS-CoV-2 (Photo courtesy of Hyris Ltd.)

A new test to detect T-cell immune response to SARS-CoV-2 leverages the power of an AI-powered platform that enables genetic testing in any setting, at any time, with results available in real-time.

Hyris Ltd. (London, UK) has developed the rapid T-Cell test to track patients' immunity levels to SARS-CoV-2 for global clinical and research use after having inked an exclusive licensing agreement with the Duke-NUS Medical School (Singapore). This new solution leverages the power of the renowned HYRIS bCUBE and the whole Hyris System. This disruptive platform enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

The Hyris System, Hyris' proprietary genetic testing platform, is an ideal Point of Care solution in the fight against COVID-19. Thanks to the power of the extremely portable proprietary hardware HYRIS bCUBE, the Hyris System works anywhere and at any time, successfully detecting the presence of coronavirus on surfaces and environments (the SARS-CoV-2 Environmental test) and COVID-19 infection in individuals (SARS-CoV-2 Human test), including all the main variants of concern that have emerged since July 2020.

The T-Cell clinical test kit developed through an exclusive licensing agreement between Hyris and Duke-NUS Medical School allows rapid and large-scale expansion of studies to track T-cell activity across the world while not requiring specialized or expensive equipment. The simple and rapid method to measure T-cell immune response to the SARS-CoV-2 virus helps to define the correlates of protection from T Cells and antibodies for the development of COVID-19 vaccines. Such a test is a prime example of how scientific innovation is the key to the fight against the SARS-CoV-2 virus in order to boost population immunity.

"Alongside with limiting the spread of SARS-CoV-2 new variants and potential hotspots, getting high immunity rates among populations is number one priority for policymakers and health institutions," said Stefano Lo Priore, Founder and CEO at Hyris. "Hyris integrated its solutions with a simple yet effective test, to measure a patient T-cell immune response to the SARS-CoV-2 virus, which causes COVID-19."

Related Links:
Hyris Ltd. 
Duke-NUS Medical School

Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
New
Silver Supplier
Automated RPR Syphilis Test
Automated RPR Test Kit
New
Anti-SARS-CoV-2 Controls Kit
ACCURUN Anti-SARS-CoV-2 Controls Kit
New
Undercounter Laboratory Refrigerator
iLR105-GX

Print article

Channels

Hematology

view channel
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)

Siemens Introduces New Intelligent, Integrated IVD Solutions Virtually at EUROMEDLAB 2021

Siemens Healthineers (Erlangen, Germany) introduced new intelligent, integrated IVD solutions virtually at the XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab... Read more

Immunology

view channel
Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)

Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers

Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing

The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.